Medroxyprogesterone Acetate Injectable Suspension Injection, Suspension
Product Images NDC 24201-150

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Medroxyprogesterone Acetate Injectable Suspension (NDC 24201-150). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hikma Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Spl Img 01 Fig 1)

This text presents the odds ratios, with their corresponding 95% confidence intervals, obtained from different studies assessing the risk of DMPA use for a minimum of 12 months in relation to various health outcomes. The odds ratios are presented on a logarithmic scale, with ratios above 1 indicating an increased risk associated with DMPA use.*

FDA Label Image

Chemical Structure (Spl Img 02 Chem Struc)

FDA Label Image

Figure 2 (Spl Img 04 Chart)

FDA Label Image

Vial Label (Spl Img 06 Vial Label)

This is a prescription medication called Medroxyprogesterone Acetate Injectable Suspension, USP that is to be administered via intramuscular use only. Each 1 mL single-dose vial contains 150 mg of the medication and should be shaken vigorously before each use. It must be stored upright and is manufactured for Hikma. The location of manufacture is Berkeley Heights with zip code 07022.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.